Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CC-92480, [14C]-CC-92480, BMS-986348
Mezigdomide · 7 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| MeziKd (Mezigdomide + Carfilzomib + Dexamethasone) | EXPERIMENTAL | - |
| Kd (Carfilzomib + Dexamethasone) | ACTIVE_COMPARATOR | - |
| MeziVd (mezigdomide, bortezomib and dexamethasone) | EXPERIMENTAL | - |
| PVd (pomalidomide, bortezomib and dexamethasone) | EXPERIMENTAL | - |
| Phase 1 | EXPERIMENTAL | - |
| Phase 2 | EXPERIMENTAL | - |
| Group A: Participants with severe renal impairment | EXPERIMENTAL | - |
| Group B: Participants with End Stage Renal Disease | EXPERIMENTAL | - |
| Group C: Participants with normal renal function | EXPERIMENTAL | - |
| Mild hepatic impairment | EXPERIMENTAL | - |
| Moderate hepatic impairment | EXPERIMENTAL | - |
| Severe hepatic impairment | EXPERIMENTAL | - |
| Healthy participants | EXPERIMENTAL | - |
| Part 1 Arm A: Dose Finding | EXPERIMENTAL | - |
| Part 1 Arm B: Dose Finding | EXPERIMENTAL | - |
| Part 1 Arm C: Dose Finding | EXPERIMENTAL | - |
| Part 2 Arm D: Dose Expansion | ACTIVE_COMPARATOR | - |
| Part 2 Arm E: Dose Expansion | EXPERIMENTAL | - |
| Part 2 Arm G: Dose Expansion | EXPERIMENTAL | - |
| Cohort A: CC-92480 with bortezomib and dexamethasone | EXPERIMENTAL | - |
| Cohort C: CC-92480 with carfilzomib and dexamethasone | EXPERIMENTAL | - |
| Cohort H: CC-92480 with elotuzumab and dexamethasone | EXPERIMENTAL | - |
| Cohort I: CC-92480 with isatuximab and dexamethasone | EXPERIMENTAL | - |
| Cohort D: CC-92480 with bortezomib and dexamethasone | EXPERIMENTAL | - |
| Cohort F: CC-92480 with carfilzomib and dexamethasone | EXPERIMENTAL | - |
| Cohort J: CC-92480 with elotuzumab and dexamethasone | EXPERIMENTAL | - |
| Cohort K: CC-92480 with isatuximab and dexamethasone | EXPERIMENTAL | - |
| Cohort G: CC-92480 with bortezomib and dexamethasone | EXPERIMENTAL | - |
| Subcohort B1: CC-92480 with daratumumab and dexamethasone | EXPERIMENTAL | - |
| Subcohort B2: CC-92480 with daratumumab and dexamethasone | EXPERIMENTAL | - |
| Subcohort B3: CC-92480 with daratumumab and dexamethasone | EXPERIMENTAL | - |
| Subcohort E1: CC-92480 with daratumumab and dexamethasone | EXPERIMENTAL | - |
| Subcohort E2: CC-92480 with daratumumab and dexamethasone | EXPERIMENTAL | - |
| Subcohort E3: CC-92480 with daratumumab and dexamethasone | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Mezigdomide | DRUG | Specified dose on specified days |
| Carfilzomib | DRUG | Specified dose on specified days |
| Dexamethasone | DRUG | Specified dose on specified days |
| Pomalidomide | DRUG | Specified dose on specified days |
| Bortezomib | DRUG | Specified dose on specified days |
| Elranatamab | DRUG | Specified dose on specified days |
| CC-92480 | DRUG | Specified dose on specified days |
| Tazemetostat | DRUG | Specified dose on specified days |
| BMS-986158 | DRUG | Specified dose on specified days |
| Trametinib | DRUG | Specified dose on specified days |
| Daratumumab | DRUG | Specified dose on specified days |
| Elotuzumab | DRUG | Specified dose on specified days |
| Isatuximab | DRUG | Specified dose on specified days |
Inclusion Criteria \- Participant has documented diagnosis of multiple myeloma and measurable disease, defined as any of the following:. i) Myeloma-protein (M-protein) ≥ 0.5 grams/deciliter (g/dL) by serum protein electrophoresis (sPEP), or. ii) M-protein ≥ 200 milligrams (mg)/24-hour urine colle...
Top 20 of 25 competitors
Mezigdomide is an investigational small molecule being developed by Bristol-Myers Squibb Company (ticker: BMY). It is being studied in multiple myeloma, including relapsed or refractory multiple myeloma, as well as in participants with renal impairment and hepatic impairment. It belongs to the -domide class of cereblon-targeting agents and is currently in clinical development.
Mezigdomide is being evaluated for relapsed or refractory multiple myeloma, including in combination with elranatamab and in combination with carfilzomib and dexamethasone. It is investigational and has not been approved for any indication. Clinical trials are assessing its safety, drug levels, and preliminary efficacy in these patient populations.
Mezigdomide targets cereblon, a component of the E3 ubiquitin ligase complex. It is a small molecule in the -domide class of cereblon-targeting agents. By binding cereblon, it modulates the ubiquitin-proteasome pathway, which is the mechanism under investigation in multiple myeloma and related conditions.
Mezigdomide is developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. Bristol-Myers Squibb is the sponsor of the clinical trials evaluating mezigdomide in multiple myeloma, renal impairment, and hepatic impairment.
Mezigdomide is in Phase 1 development for multiple myeloma and for renal and hepatic impairment studies, with a Phase 3 trial also ongoing in relapsed or refractory multiple myeloma. It is investigational and has not been approved by the FDA for any indication.
Mezigdomide is being studied in several clinical trials, including NCT06988488, a Phase 1 trial combining mezigdomide with elranatamab in relapsed or refractory multiple myeloma; NCT06318676, a Phase 1 trial in renal impairment; NCT05707390, a Phase 1 trial in hepatic impairment; and NCT05552976, a Phase 3 trial of mezigdomide plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed or refractory multiple myeloma.
Yes, mezigdomide is also known as CC-92480 and [14C]-CC-92480. These are alternative names for the same investigational compound developed by Bristol-Myers Squibb Company. The CC-92480 designation is used in some study titles and references.